Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SurModics has announced that its Brookwood Pharmaceuticals subsidiary has licensed lipid nanoparticle technology from PharmaSol of Berlin, Germany.
Subscribe to our email newsletter
Under the agreement, Brookwood has exclusive rights to all pharmaceutical applications of the technology. The PharmaSol technology can be used to formulate drugs into nanostructured lipid carriers (NLCs), which offer a number of advantages over other drug delivery nanotechnologies such as liposomes, emulsions and solid lipid nanoparticles.
Brookwood is currently offering PharmaSol technology to potential customers, while also generating additional data to accelerate product development of the NLC drug delivery platform.
Arthur Tipton, president of Brookwood, said: “This license further broadens the drug delivery technology offerings of SurModics and Brookwood and complements our existing portfolio.”